1-(diazyn-1-ium-1-yl)-4,7,10,13-tetraoxa-1-azatetradecan-1-ide, >98.0%(HPLC), 100mg

trans-Hexen-2-al, min 98.5%, for synthesis, 25 ml, glass packaging

ethyl 4-[2-[8-(1,4-dioxa-8-azaspiro[4.5]decyl)methyl]phenyl]-4-oxobutyrate, 97.0%, 1g

tert-Butyl 4-aminophenethylcarbamate, 95.0%, 1g

Furo[3,4-b]pyrazine-5,7-dione, 97.0%, 100g

3-(3-methyl-1H-1,2,4-triazol-5-yl)piperidine dihydrochloride, 95.0%, 1g

N-(2-Aminophenyl)-N-methylmethanesulfonamide, 97.0%, 1g

2-BROMO-3-VINYLPYRIDINE, 95.0%, 100mg

Ethyl 5-amino-1,2,4-oxadiazole-3-carboxylate, 95.0%, 1g

2-Bromo-1-(2-chloro-6-methoxyphenyl)ethanone, 95%, 250mg

2-(3,3-DIFLUOROCYCLOBUTYL)ACETALDEHYDE, 95.0%, 100mg

5-Amino-1,3,6-trimethyl-1,3-dihydro-benzoimidazol-2-one, 95.0%, 5g

2-Bromo-5-fluorophenol, 98.0%, 5g